Tortugas Neuroscience

Cerevel Therapeutics

This biopharmaceutical company develops neuroscience medicines for patients with mental and neurological conditions including schizophrenia, Parkinson's disease and epilepsy.

Newleos Therapeutics

The company develops oral small-molecule drugs to treat neuropsychiatric disorders, including anxiety and substance use disorders, for patients seeking therapies with fewer side effects.

Syremis Therapeutics

This biopharmaceutical company develops small-molecule oral medicines for patients with neuropsychiatric conditions, including schizophrenia, major depressive disorder and bipolar depression.

Syremis

This biopharmaceutical company develops oral small-molecule medicines for patients with schizophrenia, major depressive disorder, and other serious mental health conditions.

Kynexis

This clinical-stage biotechnology company develops precision therapeutics and small-molecule inhibitors to treat cognitive impairment in patients with schizophrenia and other neurological disorders.

Neurosciences

This company develops precision sodium channel therapeutics to treat patients with neurological conditions such as genetic epilepsy and chronic neuropathic pain.

Kasvu Therapeutics

This company develops small-molecule neuroplastogen treatments for neuropsychiatric and neurodegenerative disorders, targeting patients with major depressive disorder and brain diseases.

Engrail Therapeutics

This company develops small-molecule therapies for patients with neurologic, neuropsychiatric and neurodevelopmental disorders such as anxiety, depression and rare diseases.